These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17638515)

  • 1. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
    Steed H; Sawyer MB
    Pharmacogenomics; 2007 Jul; 8(7):803-15. PubMed ID: 17638515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of paclitaxel metabolism.
    Spratlin J; Sawyer MB
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):222-9. PubMed ID: 17092739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of importance for paclitaxel chemotherapy.
    Green H
    Pharmacogenomics; 2008 Jun; 9(6):671-4. PubMed ID: 18518845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paclitaxel].
    Díaz M; Campanero MA
    Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
    [No Abstract]   [Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.
    Ye M; Zhu Z; Fu Q; Shen K; Li DK
    Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
    Monsarrat B; Royer I; Wright M; Cresteil T
    Bull Cancer; 1997 Feb; 84(2):125-33. PubMed ID: 9180834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
    Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
    Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
    Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R; Vorlicek J; Slavik M
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
    Fruscio R; Lissoni AA; Frapolli R; Corso S; Mangioni C; D'Incalci M; Zucchetti M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):319-25. PubMed ID: 16362296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
    De Stefano I; Battaglia A; Zannoni GF; Prisco MG; Fattorossi A; Travaglia D; Baroni S; Renier D; Scambia G; Ferlini C; Gallo D
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):107-16. PubMed ID: 20848284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
    Milović-Kovačević M; Stamatovic L; Popov I; Radošević-Jelić L; Kezic I
    Med Sci Monit; 2010 Nov; 16(11):CR549-54. PubMed ID: 20980960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with the taxanes.
    Baker SD
    Pharmacotherapy; 1997; 17(5 Pt 2):126S-132S. PubMed ID: 9322879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Level of evidence for therapeutic drug monitoring for paclitaxel].
    Gerritsen-van Schieveen P; Royer B;
    Therapie; 2010; 65(3):195-200. PubMed ID: 20699070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.